How much revenue did Comirnaty generate in 2020?
Pfizer’s COVID-19 vaccine, Comirnaty (also called BNT162b2), produced the vast majority of the company’s vaccine-related sales in 2020, but exact “Comirnaty revenue” totals for that year depend on how filings define the line item (for example, whether it’s reported as total vaccine revenue vs. revenue for the product sold under the Comirnaty name).
If you’re looking for the specific figure, tell me which format you want (Pfizer total company revenue impact vs. the specific Comirnaty vaccine line item), and I’ll align it to that reporting basis.
What was Pfizer’s total revenue in 2020, and how much was Comirnaty?
In 2020, Pfizer reported a large year-over-year jump in revenue driven by Comirnaty sales, but the exact split between Comirnaty and other Pfizer revenue requires pulling the 2020 reporting table from Pfizer’s annual reporting (10-K) or earnings releases.
When did Comirnaty sales start in 2020?
Comirnaty launched in late 2020 in many markets, so most of the year’s vaccine revenue was concentrated in the final quarter rather than spread evenly across all four quarters. This timing is why 2020 vaccine revenue is usually reported as a major late-year spike compared with earlier quarters.
Where to find the exact 2020 Comirnaty revenue number in Pfizer reporting
The exact figure is typically found in:
- Pfizer’s 2020 Form 10-K segment/product revenue disclosures, where Comirnaty/BioNTech COVID-19 vaccine sales are broken out, and/or
- Pfizer’s quarterly earnings materials for Q2–Q4 2020, with Q4 showing the biggest contributions.
Quick clarification so I give you the right number
Do you want:
1) Pfizer’s reported “Comirnaty/BioNTech COVID-19 vaccine” revenue for full-year 2020, or
2) Pfizer’s total revenue for 2020 and the portion attributable to Comirnaty?
Reply with 1 or 2 (and, if you have it, your preferred currency: USD or EUR), and I’ll provide the exact 2020 revenue figure in the correct reporting context.